These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 8297742

  • 1. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [Abstract] [Full Text] [Related]

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
    Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F.
    J Clin Oncol; 1999 Oct 01; 17(10):3048-57. PubMed ID: 10506599
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 01; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
    Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D.
    Tumori; 2011 Jun 01; 97(4):532-9. PubMed ID: 21989445
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
    Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y, Sasaki T.
    Virchows Arch; 1996 Feb 01; 427(5):487-96. PubMed ID: 8624578
    [Abstract] [Full Text] [Related]

  • 11. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK, Gertz RE, Ivins CM, Kacinski BM.
    Cancer; 1995 Apr 01; 75(7):1627-33. PubMed ID: 8826920
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.
    J Clin Oncol; 1994 Aug 01; 12(8):1648-58. PubMed ID: 8040677
    [Abstract] [Full Text] [Related]

  • 13. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W, Malter W, Krämer S, Drebber U, Drzezga A, Schmidt M.
    Anticancer Res; 2014 Aug 15; 34(8):4457-62. PubMed ID: 25075085
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
    Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N.
    Breast Cancer Res Treat; 1997 Apr 15; 43(2):153-63. PubMed ID: 9131271
    [Abstract] [Full Text] [Related]

  • 16. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.
    Breast Cancer Res Treat; 1999 Mar 15; 54(2):147-57. PubMed ID: 10424405
    [Abstract] [Full Text] [Related]

  • 17. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
    Cufer T, Borstnar S, Vrhovec I.
    Int J Biol Markers; 2003 Mar 15; 18(2):106-15. PubMed ID: 12841679
    [Abstract] [Full Text] [Related]

  • 18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 19. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N, Kates RE, Schmitt M.
    J Clin Oncol; 2002 Feb 15; 20(4):1000-7. PubMed ID: 11844823
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH.
    Mund Kiefer Gesichtschir; 2004 May 15; 8(3):180-90. PubMed ID: 15138856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.